https://www.targetedonc.com/view/results-from-the-phase-3-nrg-rtog-1112-study-of-sorafenib-in-hcc
0
0
1/20/23 at 7:00pm
Organization
Targetedonc.com
42 words
0
Comments
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
You are the first to view
Create an account
or login to join the discussion